日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

普拉替尼治疗晚期RET融合阳性非小细胞肺癌患者的I/II期ARROW研究的最终疗效和安全性数据

Besse, Benjamin; Subbiah, Vivek; Curigliano, Giuseppe; Bowles, Daniel W; Doebele, Robert C; Mansfield, Aaron S; Baik, Christina S; de Lima Lopes, Gilberto; Paz-Ares, Luis; Taylor, Matthew H; Tan, Daniel S W; Alonso, Guzman; Gadgeel, Shirish M; Kalemkerian, Gregory P; Ou, Sai-Hong Ignatius; van der Wekken, Anthonie J; Becerra, Carlos R; Evangelist, Makenzi; Griesinger, Frank; Liu, Stephen V; Lou, Yanyan; Mazières, Julien; Melear, Jason M; Narang, Mohit; Saxena, Ashish; Thomas, Michael; Wang, Sophia; Thomassen, Amber; Lee, Dae Ho; Kim, Dong-Wan; Gainor, Justin F

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results

米拉德美坦治疗MDM2扩增和TP53野生型晚期实体瘤:临床前和II期临床试验结果

Dumbrava, Ecaterina E; Stinchcombe, Thomas E; Gounder, Mrinal; Cote, Gregory M; Hanna, Glenn J; Sumrall, Bradley; Wise-Draper, Trisha M; Kanaan, Mohammed; Duffy, Steven; Sumey, Christopher; Cobb, Patrick; Forbes, Andre; Beckmann, Aviva G; Schadt, Eric E; Ku, Nora; Tirunagaru, Vijaya G; Singh, Kanchan; Pei, Xinyu; Xu, Feng; Doebele, Robert C; Chen, Christopher T

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.

癌症相关成纤维细胞通过同时激活整合素和MET信号通路,使EML4-ALK驱动的肺癌对ALK抑制剂产生耐药性。

Hu Qianqian, Remsing Rix Lily L, Desai Bina, Miroshnychenko Daria, Li Xueli, Welsh Eric A, Fang Bin, Wright Gabriela M, Chaudhary Neelkamal, Kroeger Jodi L, Doebele Robert C, Koomen John M, Haura Eric B, Marusyk Andriy, Rix Uwe

Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

GATA3突变转移性激素受体阳性乳腺癌的基因组和蛋白质组分析及其对临床结果的影响

Medford, Arielle J; Velimirovic, Marko; Gefen, Yifat; Niemierko, Andrzej; Gerratana, Lorenzo; Davis, Andrew A; Clifton, Katherine; Keenan, Jennifer; Podany, Emily; Hensing, Whitney L; Reduzzi, Carolina; Dai, Charles S; Kiedrowski, Lesli A; Spring, Laura M; Ellisen, Leif W; Doebele, Robert C; Cristofanilli, Massimo; Getz, Gad; Bardia, Aditya

EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions

EGFR抑制和药物诱导的增强是致癌RTK融合的普遍特征。

Gao, Yuzhi Carol; Gonzalez-Martinez, David; Wissert, Sofia; Bader, Hana; Sahni, Nidhi; Le, Anh; Doebele, Robert C; Bugaj, Lukasz J

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study

新辅助奥希替尼治疗I-IIIA期表皮生长因子受体突变型非小细胞肺癌:一项II期多中心研究

Blakely, Collin M; Urisman, Anatoly; Gubens, Matthew A; Mulvey, Claire K; Allen, Greg M; Shiboski, Stephen C; Rotow, Julia K; Chakrabarti, Turja; Kerr, D Lucas; Aredo, Jacqueline V; Bacaltos, Bianca; Gee, Megan; Tan, Lisa; Jones, Kirk D; Devine, W Patrick; Doebele, Robert C; Aisner, Dara L; Patil, Tejas; Schenk, Erin L; Bivona, Trever G; Riess, Jonathan W; Coleman, Melissa; Kratz, Johannes R; Jablons, David M

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK -driven lung cancer via concurrent integrin and MET signaling

癌相关成纤维细胞通过整合素和MET信号通路协同作用,赋予EML4-ALK驱动的肺癌ALK抑制剂耐药性。

Hu, Qianqian; Remsing Rix, Lily L; Desai, Bina; Miroshnychenko, Daria; Li, Xueli; Welsh, Eric A; Fang, Bin; Wright, Gabriela M; Chaudhary, Neelkamal; Kroeger, Jodi L; Doebele, Robert C; Koomen, John M; Haura, Eric B; Marusyk, Andriy; Rix, Uwe

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Milademetan(一种 MDM2 抑制剂)在晚期脂肪肉瘤、实体瘤或淋巴瘤患者中的首次人体 I 期研究

Gounder, Mrinal M; Bauer, Todd M; Schwartz, Gary K; Weise, Amy M; LoRusso, Patricia; Kumar, Prasanna; Tao, Ben; Hong, Ying; Patel, Parul; Lu, Yasong; Lesegretain, Arnaud; Tirunagaru, Vijaya G; Xu, Feng; Doebele, Robert C; Hong, David S

ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression

ALK融合的非小细胞肺癌癌基因通过SERPINB4表达促进细胞存活并抑制NK细胞反应。

Chuang, Tzu-Po; Lai, Wei-Yun; Gabre, Jonatan L; Lind, Dan E; Umapathy, Ganesh; Bokhari, Abdulmalik A; Bergman, Bengt; Kristenson, Linnea; Thorén, Fredrik B; Le, Anh; Doebele, Robert C; Van den Eynden, Jimmy; Palmer, Ruth H; Hallberg, Bengt

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer

肺癌突变联盟3试验的手术结果:一项II期多中心单臂研究,旨在探讨阿特珠单抗作为新辅助治疗在IB期至IIIB期可切除非小细胞肺癌患者中的疗效和安全性

Rusch, Valerie W; Nicholas, Alan; Patterson, G Alexander; Waqar, Salama N; Toloza, Eric M; Haura, Eric B; Raz, Dan J; Reckamp, Karen L; Merritt, Robert E; Owen, Dwight H; Finley, David J; McNamee, Ciaran J; Blasberg, Justin D; Garon, Edward B; Mitchell, John D; Doebele, Robert C; Baciewicz, Frank; Nagasaka, Misako; Pass, Harvey I; Schulze, Katja; Johnson, Ann; Bunn, Paul A; Johnson, Bruce E; Kris, Mark G; Kwiatkowski, David J; Wistuba, Ignacio I; Chaft, Jamie E; Carbone, David P; Lee, Jay M